Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland

OBJECTIVES: To assess cost implications per patient, per year, and to predict the potential annual budget impact when patients with bone metastases secondary to solid tumours at risk of skeletal-related events (SREs) transition from zoledronic acid (ZA; 4 mg every 3–4 weeks) to denosumab (120 mg eve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lothgren, Mickael, Ribnicsek, Erna, Schmidt, Louise, Habacher, Wolfgang, Lundkvist, Jonas, Pfeil, Alena M, Biteeva, Irina, Vrouchou, Polina, Bracco, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717600/
https://ncbi.nlm.nih.gov/pubmed/23888248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2012-000235
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados